B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents

Arthritis and Rheumatism

Volumn 56, Issue 5, 2007, Pages 1417-1423

  Finckh, Axel ^a   Ciurea, Adrian ^b   Brulhart, Laure ^a   Kyburz, Diego ^b   Möller, Burkhard ^c   Dehler, Silvia ^d   Revaz, Sylvie ^e   Dudler, Jean ^e   Gabay, Cem ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ADJUVANT THERAPY; ADULT; ARTICLE; B LYMPHOCYTE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LONGITUDINAL STUDY; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TOTAL QUALITY MANAGEMENT; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; COHORT STUDIES; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34248545097     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22520     Document Type: Article

References (12)

1. Redlich K, Schett G, Steiner G, Hayer S, Wagner EF, Smolen JS. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum 2003;48:3308-19.
2. National Library of Medicine. URL: www.ClinicalTrials.gov.
3. Finckh A, Simard JF, Gabay C, Guerne PA. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006;65:746-52.
4. Furst D, Yocum D, Weisman M, Troum O, Bray V, Wallace D, et al. Infliximab provides additional clinical and radiographic benefits in RA patients who have an inadequate response to etanercept. Online at http://www. abstracts2view.com/eular/view.php?nu=EULAR05L1_2005SAT0058.
5. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
6. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005;353: 1114-23.
7. Uitz E, Fransen J, Langenegger T, Stucki G, for the Swiss Clinical Quality Management in Rheumatoid Arthritis. Clinical quality management in rheumatoid arthritis: putting theory into practice. Rheumatology (Oxford) 2000;39:542-9.
8. Finckh A, Simard JF, Duryea J, Liang MH, Huang J, Daneel S, et al. The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study. Arthritis Rheum 2006; 54:54-9.
9. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
10. Paulus HE, Ramos B, Wong WK, Ahmed A, Bulpitt K, Park G, et al; for the Western Consortium of Practicing Rheumatologists. Equivalence of the acute phase reactants C-reactive protein, plasma viscosity, and Westergren erythrocyte sedimentation rate when used to calculate American College of Rheumatology 20% improvement criteria or the Disease Activity Score in patients with early rheumatoid arthritis. J Rheumatol 1999;26:2324-31.
11. Buch MH, Bingham SJ, Seto Y, McGonagle D, Bejarano V, White J, et al. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor α blockade. Arthritis Rheum 2004;50:725-8.
12. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.